loading
Summit Therapeutics Inc stock is traded at $17.87, with a volume of 6.77M. It is down -2.88% in the last 24 hours and down -4.03% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$18.40
Open:
$18.02
24h Volume:
6.77M
Relative Volume:
2.34
Market Cap:
$13.18B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-10.63
EPS:
-1.6811
Net Cash Flow:
$-113.02M
1W Performance:
+0.22%
1M Performance:
-4.03%
6M Performance:
+129.10%
1Y Performance:
+636.91%
1-Day Range:
Value
$17.71
$18.60
1-Week Range:
Value
$16.83
$19.18
52-Week Range:
Value
$2.10
$33.89

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name
Name
Summit Therapeutics Inc
Name
Phone
305-203-2034
Name
Address
601 BRICKELL KEY DRIVE, MIAMI
Name
Employee
105
Name
Twitter
@summitplc
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
SMMT's Discussions on Twitter

Compare SMMT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SMMT
Summit Therapeutics Inc
17.87 13.18B 956.00K -196.68M -113.02M -0.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-11-24 Initiated Wells Fargo Overweight
Dec-06-24 Initiated Jefferies Buy
Nov-04-24 Initiated JMP Securities Mkt Outperform
Sep-27-24 Downgrade Citigroup Buy → Neutral
Aug-12-24 Initiated H.C. Wainwright Buy
May-07-24 Initiated Citigroup Buy
Mar-26-24 Initiated Stifel Buy
Jun-28-18 Downgrade Janney Buy → Neutral
May-02-18 Initiated Janney Buy
Apr-12-18 Reiterated Needham Buy
Feb-13-18 Initiated BTIG Research Buy
Jan-04-18 Initiated SunTrust Buy
Dec-01-17 Resumed H.C. Wainwright Buy
Nov-16-16 Reiterated RBC Capital Mkts Outperform
Oct-05-16 Reiterated Needham Buy
Sep-16-16 Initiated H.C. Wainwright Buy
Mar-30-15 Initiated Needham Buy
Mar-30-15 Initiated Oppenheimer Outperform
View All

Summit Therapeutics Inc Stock (SMMT) Latest News

pulisher
04:31 AM

Barclays PLC Lowers Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

04:31 AM
pulisher
Dec 20, 2024

Why Did Summit Therapeutics Inc. (SMMT) Jump Yesterday? - Insider Monkey

Dec 20, 2024
pulisher
Dec 20, 2024

Why These 10 Stocks Jumped Yesterday - Insider Monkey

Dec 20, 2024
pulisher
Dec 20, 2024

Where Will Summit Therapeutics Be in 5 Years? - Yahoo Finance

Dec 20, 2024
pulisher
Dec 20, 2024

3 Stocks That Could Turn $1,000 into $5,000 by 2030 - The Motley Fool

Dec 20, 2024
pulisher
Dec 20, 2024

Wellington Management Group LLP Has $968,000 Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

Summit Therapeutics (NASDAQ:SMMT) Trading Up 6.8%Should You Buy? - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

(SMMT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Dec 19, 2024
pulisher
Dec 18, 2024

Has Summit Therapeutics Stock Already Peaked? - AOL

Dec 18, 2024
pulisher
Dec 18, 2024

State Street Corp Sells 654,623 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Dec 18, 2024
pulisher
Dec 16, 2024

Here's Why Summit Therapeutics Stock Price Rose 6% on Friday - MSN

Dec 16, 2024
pulisher
Dec 15, 2024

2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street - Yahoo! Voices

Dec 15, 2024
pulisher
Dec 14, 2024

Virtu Financial LLC Makes New Investment in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Dec 14, 2024
pulisher
Dec 13, 2024

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Dec 13, 2024
pulisher
Dec 12, 2024

Wells Fargo Initiates Coverage of Summit Therapeutics (SMMT) with Overweight Recommendation - MSN

Dec 12, 2024
pulisher
Dec 11, 2024

Summit Therapeutics (NASDAQ:SMMT) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat

Dec 11, 2024
pulisher
Dec 07, 2024

Summit Therapeutics (NASDAQ:SMMT) Earns Buy Rating from Analysts at Jefferies Financial Group - MarketBeat

Dec 07, 2024
pulisher
Dec 07, 2024

Polar Asset Management Partners Inc. Takes Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Dec 07, 2024
pulisher
Dec 07, 2024

Why Summit Therapeutics Stock Rocketed 6% Higher on Friday - MSN

Dec 07, 2024
pulisher
Dec 06, 2024

Bank of Montreal Can Invests $2.04 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

The Manufacturers Life Insurance Company Raises Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Dec 06, 2024
pulisher
Dec 04, 2024

Warning: This Skyrocketing Stock Has a Hidden Risk - AOL

Dec 04, 2024
pulisher
Dec 04, 2024

Charles Schwab Investment Management Inc. Boosts Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Dec 04, 2024
pulisher
Dec 03, 2024

Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit - Yahoo Finance

Dec 03, 2024
pulisher
Dec 03, 2024

Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Acquired by Fmr LLC - MarketBeat

Dec 03, 2024
pulisher
Dec 02, 2024

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial - Seeking Alpha

Dec 02, 2024
pulisher
Dec 02, 2024

Summit Therapeutics Inc. (NASDAQ:SMMT) Shares Acquired by Baker BROS. Advisors LP - MarketBeat

Dec 02, 2024
pulisher
Dec 02, 2024

Billionaire Ken Griffin Is Selling Palantir and Buying a Stock Wall Street Expects to Rocket 139% Higher - Yahoo Finance

Dec 02, 2024
pulisher
Dec 02, 2024

Cerity Partners LLC Invests $2.18 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Dec 02, 2024
pulisher
Dec 01, 2024

2 Hot Biopharma Stocks to Buy and Hold for 5 Years - AOL

Dec 01, 2024
pulisher
Nov 30, 2024

Intech Investment Management LLC Invests $694,000 in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Nov 30, 2024
pulisher
Nov 29, 2024

Stock Market Movers Today • Top Gainers & Losers - Benzinga

Nov 29, 2024
pulisher
Nov 27, 2024

(SMMT) Investment Analysis and Advice - Stock Traders Daily

Nov 27, 2024
pulisher
Nov 26, 2024

Summit Therapeutics to Present at Upcoming Investor Conferences - BioSpace

Nov 26, 2024
pulisher
Nov 23, 2024

3 Monster Stocks in the Making - Yahoo Finance

Nov 23, 2024
pulisher
Nov 20, 2024

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Summit Therapeutics (SMMT) Hurt Bronte Capital. Here’s Why - Insider Monkey

Nov 20, 2024
pulisher
Nov 18, 2024

Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 18, 2024
pulisher
Nov 17, 2024

(SMMT) Trading Report - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 14, 2024

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics - Investor's Business Daily

Nov 14, 2024
pulisher
Nov 14, 2024

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters

Nov 14, 2024
pulisher
Nov 12, 2024

2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL

Nov 12, 2024
pulisher
Nov 09, 2024

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga

Nov 09, 2024
pulisher
Nov 09, 2024

Is Summit Therapeutics a Millionaire Maker? - AOL

Nov 09, 2024

Summit Therapeutics Inc Stock (SMMT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
Cap:     |  Volume (24h):